**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 66297

**Manuscript Type:** MINIREVIEWS

**Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives**

Charalampakis N *et al*. Trimodality treatment of gastric and GEJ cancer

Nikolaos Charalampakis, Sergios Tsakatikas, Dimitrios Schizas, Stylianos Kykalos, Maria Tolia, Rodanthi Fioretzaki, Georgios Papageorgiou, Ioannis Katsaros, Ahmed Adel Fouad Abdelhakeem, Matheus Sewastjanow-Silva, Jane E Rogers, Jaffer A Ajani

**Nikolaos Charalampakis, Sergios Tsakatikas, Rodanthi Fioretzaki, Georgios Papageorgiou,** Department of Medical Oncology, Metaxa Cancer Hospital of Piraeus, Piraeus 18537, Greece

**Dimitrios Schizas,** TheFirst Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens 11527, Greece

**Stylianos Kykalos,** TheSecond Propedeutic Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens 11527, Greece

**Maria Tolia,** Department of Radiation Oncology, University Hospital of Crete, Heraklion 71110, Greece

**Ioannis Katsaros,** Department of General Surgery, Metaxa Cancer Hospital of Piraeus, Piraeus 18537, Greece

**Ahmed Adel Fouad Abdelhakeem, Matheus Sewastjanow-Silva, Jane E Rogers, Jaffer A Ajani,** Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States

**Author contributions:** Charalampakis N, Tsakatikas S and Schizas D wrote the paper; Kykalos S, Tolia M, Fioretzaki R, Papageorgiou G and Katsaros I collected the data; Abdelhakeem Adel Fouad A, Sewastjanow-Silva M, Rogers EJ and Ajani AJ revised the manuscript.

**Corresponding author: Nikolaos Charalampakis, MD, PhD,** **Medical Oncologist,** Department of Medical Oncology, Metaxa Cancer Hospital of Piraeus, Mpotasi 51, Piraeus 18537, Greece. nick301178@yahoo.com

**Received:** March 25, 2021

**Revised:** June 28, 2021

**Accepted:** December 10, 2021

**Published online:** January 15, 2022

**Abstract**

Gastric and gastroesophageal junction (GEJ) cancers represent an aggressive group of malignancies with poor prognosis even when diagnosed in relatively early stage, with an increasing incidence both in Asia and in Western countries. These cancers are characterized by heterogeneity as a result of different pathogenetic mechanisms as shown in recent molecular analyses. Accordingly, the understanding of phenotypic and genotypic correlations/classifications has been improved. Current therapeutic strategies have also advanced and moved beyond surgical extirpation alone, with the incorporation of other treatment modalities, such as radiation and chemotherapy (including biologics). Chemoradiotherapy has been used as postoperative treatment after suboptimal gastrectomy to ensure local disease control but also improvement in survival. Preoperative chemoradiotherapy/chemotherapy has been employed to increase the chance of a successful R0 resection and pathologic complete response rate, which is associated with improved long-term outcomes. Several studies have defined various chemotherapy regimens to accompany radiation (before and after surgery). Recently, addition of immunotherapy after trimodality of gastroesophageal cancer has produced an advantage in disease-free interval. Targeted agents used in the metastatic setting are being investigated in the early setting with mixed results. The aim of this review is to summarize the existing data on trimodality approaches for gastric and GEJ cancers, highlight the remaining questions and present the current research effort addressing them.

**Key Words:** Gastric cancer; Gastroesophageal junction cancer; Trimodality treatment; Chemoradiotherapy; Surgery; Immunotherapy

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Charalampakis N, Tsakatikas S, Schizas D, Kykalos S, Tolia M, Fioretzaki R, Papageorgiou G, Katsaros I, Abdelhakeem AAF, Sewastjanow-Silva M, Rogers JE, Ajani JA. Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. *World J Gastrointest Oncol* 2022; 14(1): 181-202

**URL:** https://www.wjgnet.com/1948-5204/full/v14/i1/181.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v14.i1.181

**Core Tip:** Trimodality treatment combining chemotherapy, radiation and surgery is an effective management of locally advanced gastric and gastroesophageal cancers, although the extent of benefit remains to be answered in future clinical trials. Addition of newer therapeutic agents, such as immune checkpoint inhibitors may further enhance the curative potential of this approach.

**INTRODUCTION**

Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer mortality with a varying incidence worldwide[1]. The highest incidence (> 20 per 100000 in men) is seen in China, Japan, Korea, Latin America and Eastern Europe, whereas the lowest incidence (< 10 per 100000 in men) is seen in North America, parts of Africa and Northern Europe[2]. In the West, cancers located at the gastroesophageal junction (GEJ) are less frequent than in the stomach, however, incidence of GEJ cancer has been steadily rising during the last decade[3]. Only 27% of newly diagnosed GCs are localized with a 5-year overall survival (OS) rate of 30.4%, which, unfortunately, remains stable over the last 30 to 40 years[4]. Surgery is still the only chance for cure and implementation of a multimodality treatment approach is utilized to further improve survival. Advanced disease carries a dismal prognosis and treatment remains challenging with a 5-year OS rate less than 5%. Thus, despite decreasing incidence, GC and GEJ cancers remain a serious health burden globally with high mortality rates.

***Histology***

The vast majority (95%) of gastric malignant neoplasms are adenocarcinomas, which are typically classified based on anatomic location and histologic subtype by Lauren as intestinal and diffuse[5]. Two different mechanisms of carcinogenesis have been implicated for GC correlating with the two different histologic subtypes. Intestinal-type gastric adenocarcinoma has been heavily associated with Helicobacter pylori infection as well as other environmental factors, such as alcohol, processed meat, smoking, and obesity. Diffuse-type gastric adenocarcinoma usually arises from defective intracellular adhesion molecules due to loss of E-cadherin protein expression that is encoded by *CDH1* gene[6]. Genomic mutation in *CDH1* gene is the cause of the Hereditary Diffuse Gastric Cancer Syndrome, which increases the chance for diffuse gastric cancer throughout a person’s lifetime up to 70%[7].

Esophageal cancers are histologically diverse and can be either squamous cell carcinomas (SCC) or adenocarcinomas. Carcinomas of the GEJ are classified into the esophageal cancer group according to the 8th edition of American Joint Committee on Cancer/Union for International Cancer Control[8]. According to their histology and molecular characteristics, GEJ tumors may be further grouped within either esophageal or gastric cancer groups. Specifically, adenocarcinomas of the GEJ share similar molecular traits with distal esophageal adenocarcinoma and upper gastric adenocarcinoma, as highlighted in the Cancer Genome Atlas analysis discussed further in the article[9]. Each histologic subtype differs in terms of primary tumor location and somewhat in prognosis[10]. Esophageal SCC arises from the squamous lining of the esophagus through progression of premalignant precursor lesions that occur in the presence of risk factors that cause chronic irritation and inflammation, is more likely to localize near the tracheal bifurcation, has a proclivity for earlier lymphatic spread, and is associated with a poorer prognosis[11]. Tobacco and alcohol consumption are major risk factors for SCC, whereas tobacco use is a moderate risk factor for adenocarcinoma. SCC usually arises in the middle third of the esophagus (or higher), followed by the lower third and then less commonly to the upper third[12,13]. Adenocarcinomas arise in the distal esophagus or the GEJ and have been positively associated with GERD, obesity with an increased risk in people with BMI over 30 kg/m2[14]. This can be attributed partially to the increased risk of gastroesophageal reflux disease in obese individuals, which may lead to development of Barrett esophagus, a pre-malignant condition in which regular squamous epithelium of the esophagus is replaced by metaplastic columnar epithelium[15].

***Molecular classifications***

Apart from the traditional histologic subtypes, analysis from TCGA project has also classified GC into 4 different categories based on their genomic profile[4]: Tumors containing Epstein–Barr virus (EBV) account for approximately 10% of GCs and are characterized by high prevalence of DNA hypermethylation, amplification of *JAK2*, *PD-L1* and *PD-L2* genes. Moreover, nearly 80% have an amino acid-changing alteration in the *PIK3CA* gene. EBV-associated tumors are usually located in the proximal stomach and are associated with non-diffuse type. Large meta-analyses of multiple multicenter studies have concluded that EBV (+) GC has more favorable outcomes in comparison to EBV (-)[16]. Furthermore, Sohn *et al*[17] concluded that EBV (+) GC has the best prognosis among all other subtypes.

Microsatellite instability (MSI-H) is present in around 20% of GCs. Tumors showing mismatch repair deficiency contain a high rate of mutations, including mutations of genes encoding targetable oncogenic proteins and take place due to malfunctioning in the DNA repair mechanisms. These tumors are characterized by MLH1 hypermethylation and CIMP[18]. In terms of prognosis, MSI GC has worse prognosis than EBV (+) and better than genomically stable (GS) subtype, according to Sohn’s prognostic model[17]. Finally, patients with MSI-H and EBV positive tumors have shown high rates of response to immunotherapy and durable survival outcomes[18].

Chromosomally instable (CIN) tumors are the most frequent, accounting for around 50% of GCs and they usually appear at the GEJ. These tumors display marked aneuploidy and have a considerable number of genomic amplifications of key receptor tyrosine kinases, cell cycle regulation genes and transcription factors. They are associated with intestinal histology and most tumors carry *TP53* mutations and RTK-RAS activation[19]. Prognosis is similar to MSI subtype, however, CIN subtype seems to receive the largest benefit from adjuvant chemotherapy[17].

GS subtype lacks the molecular characteristics of the other three subtypes and has tumors enriched for the diffuse histologic variant, with approximately 30% of them having mutations or fusions in the CDH1 and RHOA signaling pathway. This group accounts for 20% of GCs that are characterized by the lack of high levels of aneuploidy and high metastatic potential. It carries the worst prognosis of all the subtypes and receives little benefit from adjuvant chemotherapy, according to Sohn’s model[17]. CDH1 germline mutations are usually associated with diffuse GC hereditary syndrome[7].

The TCGA project examined GEJ tumors separately in the molecular analysis of esophageal carcinoma[9]. Study results concluded that adenocarcinomas of the esophagus, including GEJ, more closely resemble GC, especially of the CIN subtype. GEJ tumors are characterized by DNA hypermethylation and while most tumors are classified to the CIN subtype, EBV or MSIH positivity is not uncommon[9].

**TREATMENT**

Curative treatment of GC can be achieved at the early stage through surgical or endoscopic resection. Other treatment modalities, such as radiation and chemotherapy, are frequently employed to increase the chances of successful resection and prevent distant relapse. Several studies have explored this combination of modalities and the ideal sequencing is yet unclear.

***Role of preoperative chemotherapy***

Preoperative chemotherapy is being employed in many different solid tumors as it offers certain advantages over postoperative therapy. Preoperative chemotherapy has a chance of reducing tumor size and facilitates surgical excision with negative margins (R0 resection)[20]. Furthermore, patients have a higher chance of completing preoperative chemotherapy rather than postoperative, due to possible postoperative complications or decrease in performance status associated with gastrectomy-related comorbidities. Prevention of distant metastases until surgery is also an important goal of preoperative chemotherapy[21]. Finally, response to preoperative chemotherapy has been shown to have prognostic value in patients with breast and rectal cancer, with patients achieving pathologic complete response (pCR) enjoying longer disease-free survival (DFS)[22]. Newer retrospective data also suggested a similar pattern for gastric and GEJ cancer[23,24], while results from the prospective trials cited below showed a trend for improved outcomes in patients achieving complete response in preoperative therapy.

***Principles of surgical excision***

Adenocarcinomas of the GEJ can be classified according to the Siewert classification, into type I, which arise from the distal esophagus, type II which is true junctional carcinoma of the cardia/esophagus and type III, which is subcardial carcinoma may invade the GEJ from below[25]. The extent of gastrectomy as well as the reconstruction technique used depends on tumor location. Gastrectomy is accompanied by lymph node dissection, which can be classified as D1, D2 or D3 dissection. D1 Lymphadenectomy includes all N1 nodes (perigastric nodes) whereas D2 Lymphadenectomy consists of removal of both N1 and N2 nodal groups (distant perigastric nodes and nodes along main arteries supplying the stomach)[26]. D3 Lymphadenectomy is an extensive resection including N3 nodes (para-aortic lymph nodes). D2 resection has been proved to have an advantage in improving OS, however D3 dissection failed to show any benefit in comparison to D2, and is associated with increased postoperative morbidity[27].

***Role of radiotherapy***

Radiation therapy has been employed as a mean of local tumor control in most solid tumors, including gastric cancer. Ionizing radiation targets cells during their proliferative phase, and tumor cells are more susceptible to radiation damage than regular tissue cells[28]. Radiotherapy may be used with a curative or palliative intent, depending on the total dose received and the urgency for local tumor control. In metastatic gastric and gastroesophageal cancer, radiation has been used to alleviate symptoms such as bleeding, pain and obstruction with variable but generally satisfying results in different observation studies[29]. In the early setting, radiation is being used concomitantly with chemotherapy to achieve better tumor control before or after surgical excision. Whether the addition or the timing of radiation therapy to standard chemotherapy offers additional clinical benefits remains the question of ongoing clinical trials which will be further discussed in this paper.

***Combination of chemotherapy and radiotherapy***

Chemotherapy is being used concomitantly or sequentially with radiotherapy in the treatment of many localized solid tumors. Definitive chemoradiation is the modality of choice in locally advanced head and neck cancers, lung and rectal cancers[30]. Apart from the separate cytotoxic effects of each type of treatment, concurrent use of chemotherapy and radiotherapy has shown to produce a synergistic effect that enhances antitumor response, which is more apparent than when used sequentially[31]. Chemotherapy acts as a radiosensitizer, probably by allowing cells to inappropriately progress through the S phase of the cell cycle, thus not permitting to repair the DNA damage caused by radiation[32]. Furthermore, combination treatment modulates tumor microenvironment[33], and allows for simultaneous control of both systemic micrometastases and local disease. Radiation and chemotherapy combination has been thoroughly studied and has solidified its role in the treatment of gastric and esophageal cancer, particularly in locally advanced SCC of the esophagus, where disease control can be achieved with chemoradiation alone and surgery can be reserved for refractory or relapsed disease[34].

***Addition of immunotherapy***

Recently, with the increasing use of checkpoint inhibitors, significant interaction has been noted between immunotherapy and radiotherapy that may lead to increased antitumor response. One possible mechanism to explain this effect is the release of tumor neoantigens in the tumor microenvironment after cellular destruction due to radiation. Exposure of stromal immune cells to tumor neoantigens may induce an anti-tumor response, further enhanced by the presence of immune checkpoint inhibitors[35]. Several preclinical data support this notion. For example, a study by Deng *et al*[36] in mouse models of breast and colorectal cancer showed that combination of radiation and PD-L1 inhibitors, controlled tumor growth more effectively than radiation or immunotherapy alone (587.3 ± 169.1 mm with anti–PD-L1 alone *vs* 25.59 ± 10.26 mm with radiation plus anti–PD-L1*, P* = 0.0022, 402.8 ± 76.73 mm with radiation alone *vs* 25.59 ± 10.26 mm with radiation plus anti–PD-L1, *P* = 0.0002).

**Postoperative chemoradiotherapy:** Addition of radiotherapy to chemotherapy after gastrectomy has been explored in several trials (Table 1). A classic study by Macdonald *et al*[37] examined the effectiveness of adding postoperative chemoradiotherapy to surgical resection in patients with adenocarcinoma of the stomach and GEJ. The trial included a total of 556 patients which were randomized to receive surgery alone or surgery with postoperative chemoradiotherapy. Most patients (67%) had T3 disease and positive lymph nodes (84%). Gastric antrum was the most common primary tumor location. However, more than half of the patients underwent suboptimal lymph node dissection (54% D0, 36% D1, 10% D2). Chemotherapy consisted of 5-fluorouracil (5-FU) and leucovorin and was administered concurrently with radiation. Addition of chemoradiotherapy increased OS to 36 mo, in comparison to 27 mo in the surgery-only arm, in a statistically significant manner. Grade 3 adverse events were more common in patients in the chemoradiotherapy arm[37].

Similarly, a phase II study by McNamara *et al*[38] tested the effectiveness of adjuvant chemoradiotherapy with cisplatin and 5-FU after neoadjuvant chemotherapy with epirubicin, oxaliplatin and 5-FU, in patients with resectable adenocarcinoma of the esophagus and GEJ. 60 patients were recruited and GEJ was the most common primary tumor location. An objective response was achieved in 41% of the patients and a pCR in 5% of them. The 3-year locoregional control rate reached 84% and distant metastasis control rate was 44%, while total relapse free survival was projected at 39%. 3-year OS rate was calculated at 42%. Clinical response to induction therapy was strongly associated with better outcomes[38].

Another small phase II study by Adelstein *et al*[39] examined the effectiveness of postoperative chemoradiotherapy in patients with locally advanced tumors of the esophagus and GEJ. The study enrolled 50 patients in total. Among them, 43 patients were diagnosed with adenocarcinoma, 36 had a tumor located in the GEJ and 86% of patients had node-positive disease. The study also included 3 patients with M1a disease. In the overall study population, the 4-year projected OS was 51%, freedom from recurrence was 50% and distant metastases control rate was 56%. No major difference was observed among different patient subgroups, apart from disease stage and a marginal benefit for patients with SCC in comparison to adenocarcinoma[39].

A retrospective pooled analysis by Dikken *et al*[40] evaluated the effectiveness of adjuvant chemoradiotherapy in comparison to surgical excision alone in 91 patients with GC from two phase I/II studies and 694 patients from the Dutch Gastric Cancer Group Trial (DGCT). Patients in the DGCT group underwent only surgery and were randomly assigned to D1 or D2 Lymph-node dissection. Patients in the phase I/II trials received chemotherapy with 5-FU and leucovorin, capecitabine alone or capecitabine with cisplatin. Local recurrence at 2 years was significantly higher in the surgery-only group (17% *vs* 5%) in the overall study population. Subgroup analysis according to the extent of lymph node dissection showed a statistically significantly lower recurrence rate in the chemoradiation arm in the D1 subgroup (2% *vs* 8%); however, no difference was observed in patients that had D2 surgery. Chemoradiation also improved outcomes of patients that underwent surgical excision with microscopically positive margins (R1 resection)[40].

A recent Turkish retrospective analysis of 354 patients with resectable GC associated postoperative chemoradiation with improved relapse free survival (RFS), albeit the percentage of patients that underwent D2 lymph node dissection is unclear. Median RFS in the whole study population reached 53.2 mo and median OS 136 mo. Interestingly, another factor associated with an increased risk for relapse was preoperative hypoalbuminemia[41].

More recent trials, using optimized surgical techniques, have presented interesting data on the benefit of adjuvant chemoradiotherapy. A phase III trial by Xie *et al*[42] in 144 patients with locally advanced GC, staged as T3-4/N1-3 were randomized to receive either adjuvant capecitabine plus oxaliplatin or the same regimen with the addition of radiotherapy, after completion of D2 gastrectomy. 3-year disease-free survival did not differ significantly between arms, with 76.3% in the chemotherapy arm and 72.8% in the chemoradiation arm. A similar pattern was noted for OS. Rate of local RFS was also similar between arms, with no added benefit seen from the addition of radiotherapy. Similarly, no difference was noted in DFS in patients with lymph-node positive disease[42].

In a similar manner, the ARTIST study[43] compared the effectiveness of adding radiotherapy to adjuvant chemotherapy in prolonging DFS and OS in patients with GC. Investigators recruited 458 patients with GC that underwent gastrectomy with D2 Lymph node dissection. Over 80% of patients in each cohort had positive lymph nodes and the majority of patients had stage II and III disease. Most common location of the primary tumor was the body of the stomach. Patients were also stratified according to Lauren classification and around 60% in each arm belonged to the diffuse subtype. Patients were randomly assigned to either adjuvant chemotherapy with six cycles of capecitabine and cisplatin or to two cycles of capecitabine and cisplatin followed by chemoradiotherapy and two cycles of cisplatin and capecitabine after completion. DFS and OS showed no statistically significant difference among the two cohorts in the study’s overall population. The only subgroups that seemed to derive a statistically significant benefit in DFS and OS from the addition of radiotherapy were patients with lymph node positive disease and intestinal subtype. Patients with stage III or IV disease showed a trend towards improvement, without reaching statistical significance[43].

Another study pointing to the same direction was CRITICS phase III study[44], in which 788 patients with gastric and GEJ adenocarcinomas were enrolled and randomized to receive either adjuvant chemotherapy with combination of epirubicin, cisplatin or oxaliplatin and capecitabine or adjuvant radiation therapy concurrently with cisplatin and capecitabine. All patients received preoperative chemotherapy and 741 patients underwent gastrectomy with at least D1+ lymph node dissection. Of them, 478 patients received adjuvant therapy in their respective cohorts. Lauren histologic subtypes were equally represented within each cohort and only 17% of patients in each cohort had cancer of GEJ. Almost half of the patients in each cohort had node-negative disease after gastrectomy. Median OS was higher in the chemotherapy group *vs* the chemoradiotherapy group (43 mo *vs* 37 mo) although this difference did not reach statistical significance in any subgroup[44].

The recent ARTIST 2 trial[45] evaluated the addition of oxaliplatin or oxaliplatin and radiotherapy to adjuvant treatment of patients with stage II or III GC who underwent gastrectomy and D2 Lymph node dissection with positive lymph nodes. 538 patients were randomized into three cohorts according to the type of adjuvant treatment and were stratified according to the type of surgery, stage, and Lauren subtype. Patients in the first cohort received adjuvant S-1, in the second S-1 plus oxaliplatin and S-1 plus oxaliplatin and chemoradiotherapy in the third cohort. DFS was significantly lower in the S-1 only arm in comparison to S-1 plus oxaliplatin and S-1 plus oxaliplatin and chemoradiation, while there was no statistically significant benefit with the addition of radiotherapy. Interim results met the pre-specified endpoints sufficiently and the trial was terminated earlier than planned[46].

Postoperative chemoradiotherapy has improved local control rates and improved disease-free survival in earlier studies before adjuvant chemotherapy became standard of care in gastric and GEJ cancer. Although certain benefit in local control might exist for patients with less than D2 Lymphadenectomy, results from randomized phase III CRITICS and ARTIST 2 studies showed no additional benefit in clinical outcomes in comparison to adjuvant chemotherapy.

**Preoperative chemoradiotherapy:** The benefit of adding radiotherapy to preoperative chemotherapy in the management of GC has been a topic of debate, with many highly heterogeneous studies reporting conflicting results. Several small studies have been conducted, evaluating feasibility and effectiveness (Table 2).

A phase II study by Rivera *et al*[47] aimed to determine the benefit of adding chemoradiotherapy to preoperative chemotherapy with irinotecan and cisplatin in 23 patients with resectable, locally advanced, stage II-IV adenocarcinoma of the stomach and GEJ. Patients received two courses of irinotecan and cisplatin followed by irinotecan and cisplatin plus external beam radiation. In patients without progression, surgical resection was performed. Among the evaluable patients, 2 achieved pCR. Median OS was 14.5 mo and 2-year OS rate reached 35%[47].

The phase II RTOG 9904[48] study evaluated the effectiveness of neoadjuvant chemoradiotherapy in patients with resectable GC. 49 patients were enrolled and received preoperative chemotherapy with cisplatin, 5-FU and leucovorin concurrently with radiation, followed by surgery. The majority of patients had stage III disease. pCR and R0 rates reached 26% and 77% respectively and pCR was associated with favorable prognosis, in accordance with other previous studies. D2 resection was performed in only 50% of the patients[48].

A few other small studies have evaluated trimodality treatment in patients with esophageal and GEJ carcinomas. The phase II S0356 study[49] explored the impact of neoadjuvant chemoradiotherapy in patients with clinical stage II-III esophageal and GEJ adenocarcinomas. The study enrolled 93 patients, including 36 patients with adenocarcinomas of GEJ, who received a neoadjuvant combination of oxaliplatin and 5-FU and radiotherapy followed by surgical excision. After surgery, patients were planned to receive adjuvant chemotherapy with oxaliplatin and 5-FU. Genomic analysis of DNA and mRNA was also performed, seeking potential new prognostic and predictive biomarkers. The primary objective of this study was to achieve a pCR rate of 40%. 79 patients underwent surgery and 67.7% achieved R0 resections, 26 patients (28%) achieved pCR, thus not reaching the pre-specified endpoint of 40% and estimated median OS and 3-year OS were 28.3 mo and 45.1%, respectively. In terms of genomic analysis, ERCC-1 gene expression was associated with worse PFS and OS[49].

A similar phase II study by Ilson *et al*[50] evaluated the effectiveness of preoperative chemoradiation in patients with esophageal and GEJ carcinoma. The study included 55 patients in total, with both squamous (22%) and adenocarcinoma (75%) histologies. Primary tumor location was the GEJ in 33% of the patients. Patients received induction chemotherapy with combination of cisplatin and irinotecan, followed by concurrent chemoradiation. Out of them, 16% achieved pCR and median OS reached 31.7 mo. Patients were also evaluated for correlation between positron emission tomography (PET) response to induction chemotherapy and pCR rate, R0 resection rate, PFS and OS. PET response was significantly associated with higher pCR rate, PFS and chance of R0 resection. OS was increased in PET-responders, although not in a statistically significant manner[50]. Due to positive results from the addition of radiotherapy to neoadjuvant chemotherapy from single arm trials, direct comparison with a chemotherapy or surgery only approach has been employed in smaller phase II studies and paved the way for larger phase III trials.

A phase II randomized trial on the effectiveness of trimodality treatment by Ajani *et al*[51] randomized 126 patients with esophageal and GEJ carcinoma to neoadjuvant chemoradiotherapy with or without induction chemotherapy with oxaliplatin and 5-FU, followed by surgical resection. 122 patients (96.8%) were diagnosed with adenocarcinoma and 122 patients (96.8%) had tumors located in the GEJ. Median OS was 45.6 mo for all patients, with median OS being 45.6 mo in the no-induction arm and 43.6 mo in the induction arm, with this difference not reaching statistical significance. The pCR rate was numerically higher in the induction chemotherapy arm (26% *vs* 13%)[51].

Similarly, the POET trial[52] recruited 119 patients with locally advanced GEJ adenocarcinoma (Siewert types I-III) and randomized them to receive either chemotherapy with cisplatin and 5-FU alone or chemotherapy and chemoradiation. Patients in both cohorts were treated with surgical resection afterwards. Local PFS after tumor resection was significantly improved in the chemoradiation arm and there was a trend towards improvement of OS, without reaching the pre-specified endpoint for statistical significance[52].

Accordingly, the NeoRes study[53] conducted in Norway and Sweden recruited 181 patients with malignant tumors of the esophagus and GEJ. The most prevalent histologic type was adenocarcinoma (72% of patients) and 17% of tumors were located in the GEJ. Patients were equally randomized to receive neoadjuvant chemotherapy alone or with the addition of radiotherapy. The pCR rate was higher in the chemoradiation arm and lymph node positivity was lower at the time of surgery. OS did not differ between the two arms. Later results confirm that the addition of radiation to neoadjuvant chemotherapy did not significantly affect 5-year PFS and OS[53,54].

Despite the large number of trials addressing this topic, conclusions cannot be clearly drawn, due to a large number of confounding factors, low adherence to treatment protocols and high group heterogeneity. A meta-analysis by Zhao *et al*[55] of six clinical trials, including the ones by Stahl and Klevebro, that included 866 patients with adenocarcinoma and SCC of the esophagus and GEJ, concluded that 3-year and 5-year OS rates were improved with the addition of radiotherapy to neoadjuvant chemotherapy in a statistically significant manner. Furthermore, neoadjuvant chemoradiotherapy increased the chance of R0 resection and pCR. This benefit seems to apply to patients with both adenocarcinomas and SCCs[55].

Larger phase III trials have attempted to produce more robust evidence and provide definitive answers on the benefit of trimodality treatment. A small phase III trial CALGB 9781[56] evaluated the use of trimodality treatment with chemotherapy including cisplatin, 5-FU and radiotherapy before surgical resection of esophageal or GEJ carcinomas. The trial was terminated early due to poor accrual and only 56 patients were evaluable for response. 23 patients in the chemoradiotherapy cohort and 19 in the surgery-alone cohort had adenocarcinomas (77% and 73%, respectively). In the overall study population, median OS reached 4.48 years in comparison to 1.79 years with surgery-alone arm. However, the final population study was small, and no further data on different subgroups were evaluable[56].

The largest dataset from a randomized clinical trial currently available is from the CROSS phase III trial[57], which evaluated the effectiveness of neoadjuvant chemoradiotherapy in patients with resectable esophageal and GEJ carcinomas. 366 patients were randomly assigned to receive either combination of weekly carboplatin and paclitaxel with concurrent radiotherapy over a 5-wk period and then proceed to surgical resection, or to surgery-alone. The study included patients with different histologies, with the majority being adenocarcinomas (75%). In 88 patients, the primary tumor location was GEJ. Around 65% of patients in each cohort had lymph-node positive disease. Patients in the chemoradiotherapy group achieved a statistically significant higher degree of R0 resections in comparison to surgery alone (92% *vs* 69%), while 29% in the chemoradiotherapy group achieved pCR at the end of neoadjuvant treatment. Postoperative complications were similar between the two subgroups, and OS was significantly improved in the chemoradiotherapy group (49.4 mo *vs* 24.0 mo). In subgroup analysis, patients with node-negative disease at diagnosis and patients with squamous histology received clear benefit, while patients with adenocarcinoma showed a clear trend towards improvement[57].

Although CROSS study[44] proved that neoadjuvant chemoradiotherapy leads to improved outcomes in comparison to surgery alone, data from MAGIC trial[58] show also improved OS with preoperative chemotherapy, while FLOT4 trial[59] identified FLOT as a superior regimen. Thus, the ideal neoadjuvant approach is still unclear and the benefit of trimodality therapy is still under discussion.

Recent results from the phase III Neo-AEGIS are the first comparative data available answering this question. Neo-AEGIS is a phase III randomized European study comparing the efficacy and safety of preoperative chemoradiation, per CROSS study protocol, to chemotherapy alone, per MAGIC or FLOT4 protocol in patients with resectable esophageal and GEJ adenocarcinomas[60]. The study initially attempted to prove superiority of the CROSS regimen over chemotherapy, however after the first futility analysis a non-inferiority approach was adopted. Chemotherapy alone reached the primary endpoint of non-inferiority in terms of 3-year OS [57% for chemotherapy *vs* 56% for chemoradiation hazard ratio (HR) 1.02 (95%CI: 0.74-1.42)]. Of note, more patients in the CROSS arm achieved pCR and significant tumor shrinkage, in accordance with results from earlier clinical trials showing improved tumor local control with preoperative chemoradiation[60].

Results from the TOPGEAR study[61] are also awaited. TOPGEAR is an ongoing international phase III trial in patients with adenocarcinoma of the stomach and GEJ receiving induction perioperative chemotherapy with epirubicin/cisplatin/5-FU (ECF) alone or in combination with preoperative chemoradiation. The ECF group receives three preoperative cycles of ECF, while the chemoradiation group receives two cycles of ECF followed by chemoradiation. After surgical excision, patients in both groups are receiving three cycles of ECF. An interim analysis of 120 recruited patients indicated that 90% in the ECF group and 85% in the chemoradiotherapy group underwent gastrectomy. Results on effectiveness and comparison among groups are pending[61].

Analysis of recent real-world data can also add to the existing knowledge on the management of operable gastroesophageal cancer. A study of 1916 patients from the nationwide Netherlands Cancer Registry (NCR)[62], with esophageal or GEJ cancer undergoing curative treatment, with surgery or definitive chemoradiation, reported on real-world treatment outcomes. The majority of patients underwent surgery and only 21% received definitive chemoradiation. Out of patients with resected disease, 83% underwent neoadjuvant chemoradiation and 10% neoadjuvant chemotherapy, with or without adjuvant chemoradiation. Only 7% received surgery alone. Patients that received definitive chemoradiation had shorter median DFS (14.2 mo *vs* 26.4 mo) and median OS (20.9 mo *vs* 40.5 mo) than patients that underwent surgical resection. However, median age was higher and performance status was worse in the definitive chemoradiation group. Patients that received neoadjuvant chemoradiation had a median DFS of 25.2 mo and a median OS of 38 mo. Interestingly, this study included a separate subgroup analysis of patients that received adjuvant nivolumab after trimodality treatment with chemoradiation and surgery, as part of CheckMate-577 trial. Among these patients the median DFS and median OS were 19.2 and 29.4 mo, respectively[62].

Another retrospective study by Spencer *et al*[63] evaluated the role of neoadjuvant chemoradiation in patients with stage III or IVA locally advanced (T3/T4) adenocarcinoma of the esophagus and GEJ, followed by surgical resection. Patients with threatened circumferential resection margin by imaging received neoadjuvant chemoradiation, while those without a threatened margin received neoadjuvant chemotherapy. Patients that received neoadjuvant radiation also received a combination of carboplatin and paclitaxel. Most patients in the chemotherapy group received a platinum-fluoropyrimidine doublet. In total, results from 81 patients were reported. 18 patients received chemoradiation and 63 patients chemotherapy alone. Both groups included 5 patients with stage IVA disease. Rates of R0 resection were higher in the chemoradiation group and rate of local relapse was lower in comparison with the chemotherapy group. However, no difference was noted in OS and RFS. R1 resection in the chemotherapy group was a negative prognostic factor[63].

Jurkowski *et al*[64] reported on the outcomes of patients with locally advanced esophageal and GEJ adenocarcinomas treated with total neoadjuvant therapy, including induction chemotherapy followed by chemoradiation. Induction chemotherapy included doublet or triplet regimens of 5-FU, cisplatin or oxaliplatin and docetaxel, while carboplatin and paclitaxel, or oxaliplatin and 5-FU were used concurrently with radiation. 37 out of 59 evaluable patients underwent surgical resection. 9 patients opted out of surgery since they achieved clinical complete response. Among the patients who received surgery, R0 rate was 89% and pCR rate was 19%. For the entire population of the study, median DFS was 2.4 years and median OS 4.7 years. Patients who underwent surgery had a higher DFS and median OS (3.5 years *vs* 1.5 years and 5.8 years *vs* 4.2 years). The subgroup that achieved clinical complete response had worse 3-year DFS in comparison to operated patients with pCR (42% *vs* 83%), however 3-year OS was improved (89% *vs* 83%)[64].

Preoperative radiation is frequently employed in patients with gastroesophageal cancer and represents the standard of care in some many high-volume centres. Prospective and retrospective date suggest a role for preoperative chemoradiation in improving local tumor control and achieving higher pCR rates. Whether this translates to long-standing improvement in overall survival remains the subject of ongoing clinical trials, such as TOPGEAR and Neo-AEGIS. While Neo-AEGIS showed non-inferiority of preoperative chemotherapy to the CROSS regimen, it is unclear whether addition of chemoradiation to induction chemotherapy would maximize clinical benefit until results from the TOPGEAR study are announced. Moreover, only 27 of 184 patients in the chemotherapy-alone arm received FLOT, which has proved to be superior to the MAGIC regimen[59].

***Combination with newer therapeutic agents***

Newer treatment modalities have been constantly added to the therapeutic arsenal in metastatic gastroesophageal cancer. Targeting agents, such as anti-HER2 antibodies, and immune checkpoint inhibitors, as well as new predictive and prognostic biomarkers have all prolonged survival and improved quality of life in patients with unresectable disease[65]. Several modalities are being investigated in the early setting and some have already produced encouraging results (Table 3).

**Chemoradiation and immunotherapy:** The first trial of immunotherapy to produce positive results in early gastroesophageal cancer is CheckMate 577[66]. It is a global, multi-center, randomized, double-blind phase III study that explores the addition of anti-PD1 checkpoint inhibitor nivolumab to trimodality treatment for esophageal and GEJ carcinoma. 794 patients with resected, stage II/III, esophageal/GEJ carcinoma who received neoadjuvant chemoradiation and did not achieve a pCR were randomized 2:1 to receive nivolumab 240 mg every 2 wk for 16 wk, followed by 480 mg every 4 wk up to 1 year or placebo. Most dominant histology was adenocarcinoma (71%) and most patients had positive lymph nodes (60%). The primary endpoint of the study was median DFS, which was doubled with the addition of nivolumab in comparison to placebo (22.4 mo *vs* 11.0 mo). Severe treatment-related adverse events (TRAEs) occurred in 8% of nivolumab patients and 3% of placebo patients. The most common TRAEs were fatigue, pruritus, diarrhea and rash. Grade 3 immune related adverse events occurred in less than 1% of patients in the nivolumab arm[66].

Apart from the proven benefit of nivolumab, a newer phase II[67] study is examining the role of adding durvalumab to neoadjuvant chemoradiotherapy in patients with esophageal and GEJ adenocarcinoma. Study design was based on the results of CALGB 80803[68], a study that evaluated response to induction chemotherapy by PET/computed tomography (CT). After 2 cycles of mFOLFOX6, PET responders received chemoradiation with capecitabine and oxaliplatin and radiation to 50.4 Gy, while PET non-responders switched to different chemotherapy regimen of carboplatin/paclitaxel concurrent with radiation. Durvalumab was added to all patients, 2 wk before chemoradiation and was continued during chemoradiation, and was continued after R0 resection. According to preliminary data, 36 patients have been recruited, 25 with adenocarcinoma of GEJ and 11 with adenocarcinoma of the esophagus. Out of them, 72% showed disease response to induction chemotherapy at PET/CT. 25 patients underwent surgical resection and 6 achieved pCR, while 5 patients were downstaged to ypT1N0 and 2 patients to ypT0N1, showing 99% response. Another 20 patients had more than 90% response. Grade 3/4 neutropenia was observed in 8 patients and grade 3 hepatitis in 1 patient. More data are still pending[67].

Immunotherapy has gained importance in gastric and gastroesophageal cancer due to recent results from first-line phase III studies (Checkmate 649, Keynote 570) showing efficacy in the metastatic setting. As a result, combination of chemotherapy and immunotherapy is being used earlier in the therapeutic algorithm. CheckMate 577 is the first study to prove the benefit of adding postoperative immunotherapy in patients with gastroesophageal cancer and residual disease following preoperative chemoradiation. Ongoing and future studies will address the question of incorporating immunotherapy in trimodality treatment of gastric cancer, either concurrently or sequentially with chemotherapy and/or radiation therapy.

**Combinations with targeted therapies:** Given the effectiveness of anti-HER2 antibody trastuzumab in the management of advanced HER2 overexpressing GC, several trials have evaluated the benefit of HER2 inhibition in the early setting in combination with trimodality treatment.

The phase III RTOG 1010 trial[69] evaluated the effectiveness of adding the anti-HER2 agent trastuzumab concurrently with chemoradiation in patients with resectable, HER2 overexpressing (determined by immunohistochemistry and fluorescence in situ hybridization) adenocarcinoma of the esophagus and GEJ. Chemoradiotherapy consisted of carboplatin and paclitaxel and radiation of 50.4 Gy of 3D-chemoradiation therapy or intensity modulated radiotherapy. Trastuzumab was administered throughout the chemoradiation period and for 13 more cycles after surgery. In total, 203 patients were randomized to receive neoadjuvant chemoradiotherapy with or without trastuzumab. The study did not reach its primary objective, which was statistically significant improvement in DFS. Median DFS was 19.6 mo in the experimental arm and 14.2 mo in the control arm (HR 0.97, 95%CI: 0.69-1.36). Median OS also did not differ between the two arms[69].

The phase II TOXAG study[70] also evaluates the safety and efficacy of adding trastuzumab to neoadjuvant chemoradiation with oxaliplatin, capecitabine and radiation in patients with HER2+ adenocarcinoma of the stomach and GEJ who will undergo curative surgical resection. 212 patients have been screened and 34 underwent surgical resection. The combination regimen of oxaliplatin, capecitabine, trastuzumab and radiation has achieved a high rate of tolerability of 90.3% and 97% of patients achieved D2 Lymph node dissection. At 25 mo follow-up, 59.8% of patients were still alive, and 12 patients have died because of disease progression. More data on effectiveness of treatment are still pending[70].

Smaller studies have investigated anti-EGFR antibody cetuximab and anti-VEGF antibody bevacizumab in combination with chemoradiotherapy and surgery. In the phase III SAKK 75/08 trial[71], 300 patients with esophageal cancer were randomly assigned to receive neoadjuvant chemoradiation with or without the anti-EGFR antibody cetuximab, followed by surgical resection. More than half of patients (63%) were diagnosed with adenocarcinoma. Chemoradiotherapy consisted of cisplatin and docetaxel and radiation of 45 Gy. Cetuximab was given throughout chemoradiation and as adjuvant monotherapy after surgery. The study did not meet its primary endpoint, which was a statistically significant improvement in PFS [2.9 years in cetuximab arm *vs* 2 years in control arm (HR 0.79, 95%CI: 0.58-1.07; *P* = 0.13)]. Median OS was numerically improved (5.1 years *vs* 3 years) but this difference did not reach statistical significance. Similarly, subgroup analysis did not show any advantage with the addition of cetuximab, regardless of histologic type. However, locoregional control was significantly better in the cetuximab arm[71].

A phase II study by Ku *et al*[72] examined the effectiveness of adding the anti-VEGF antibody bevacizumab to preoperative induction chemotherapy and chemoradiation with cisplatin and irinotecan in patients with resectable locally advanced esophageal and GEJ adenocarcinomas. The final evaluable population of the study consisted of 33 patients, all with cancer of the GEJ. 25 patients achieved R0 resections after neoadjuvant treatment with a pCR rate of 15%. Median PFS and OS were 15.1 mo and 30.5 mo, respectively[72].

Anti-HER2 and antiangiogenic agents have improved clinical outcomes in patients with metastatic gastric and gastroesophageal cancer. However, in the early setting, targeted agents combined with standard of care have not yet produced satisfactory results. The phase III RTOG 1010 of trastuzumab plus chemoradiation has failed to prove additional clinical benefit with the addition of trastuzumab. The anti-EGFR agent cetuximab did not improve PFS in the phase III SAKK 75/08 in comparison to standard chemoradiotherapy alone. Comparative data are not yet available on the use of anti-VEGF agents.

***Choice of chemotherapy regimen***

As mentioned, there is an adequate amount of evidence on the addition of radiation therapy to chemotherapy in resectable gastric and GEJ cancer. However, as mentioned in the studies above, it is clear that there is heterogeneity concerning the chemotherapy regimen used. Several efforts have been made to identify the ideal chemotherapy regimen to partner with preoperative or postoperative radiation (Table 4).

A retrospective study by Jiang DM *et al*[73] compared carboplatin plus paclitaxel with cisplatin plus fluorouracil as chemotherapy regimens in patients with resectable tumors of the esophagus and GEJ that received neoadjuvant chemoradiotherapy. The study also included patients who did not proceed to surgical resection and received definitive chemoradiation. 93 patients with esophageal (49%) and GEJ (51%) tumors that received neoadjuvant (72%) or definitive (28%) chemoradiation were identified. 53 patients had received cisplatin-5-FU and 40 carboplatin-paclitaxel. 59 patients were diagnosed with adenocarcinoma and 34 with SCC. In patients who received surgery, no difference was observed between the two treatment groups. However, in the definitive chemoradiation subgroup, carboplatin-paclitaxel was associated with significantly worse 3-year OS (36% *vs* 63% *P* = 0.001 HR 3.1, 95%CI: 1.2-7.7) and DFS (0% *vs* 41%; *P* = 0.004; HR 3.6, 95%CI: 1.4-8.9)[73].

In the phase II, ECOG E7296 study[74], patients with carcinomas of the stomach and GEJ received adjuvant chemoradiation after induction chemotherapy and surgical resection. 38 patients were enrolled and among them, 36 were diagnosed with adenocarcinoma and 21 with tumor of the GEJ. Induction chemotherapy consisted of cisplatin and paclitaxel, while adjuvant chemotherapy of leucovorin and 5-FU. No pCR was noted after induction chemotherapy and only 3 out of 38 patients completed treatment per protocol design. Median OS in the overall population was 1.6 years. The regimen used in this study was evaluated to be highly toxic and, thus, further development was discouraged by the investigators[74].

Another study, CALGB 80803, a phase II study[68] attempted to individualize chemotherapy in patients with resectable esophageal and GEJ adenocarcinomas receiving preoperative chemoradiation, by using early PET/CT scan. 241 patients were enrolled and were randomized to receive induction chemotherapy with either FOLFOX6 or carboplatin/paclitaxel and were subsequently evaluated with PET scan. PET non-responders switched to the opposite arm during chemoradiation. Median OS was 48.8 mo for PET responders and 27.4 mo for PET non-responders. Among patients who did not respond to induction chemotherapy, 18% in the induction FOLFOX arm and 20% in the carboplatin/paclitaxel arm achieved pCR by switching to the alternative regimen during chemoradiation[68,75,76] . Remarkably, pCR rates in responders that received induction with FOLFOX reached 40.3%[76].

E1201 is a phase II randomized clinical trial[77] comparing neoadjuvant chemoradiotherapy regimens of cisplatin-paclitaxel and cisplatin-irinotecan in patients with resectable adenocarcinomas of the esophagus and GEJ. At the end of the study, 81 patients had received trimodality treatment and were evaluable for response rate, DFS and OS. The GEJ was the primary tumor location in 60 patients. Patients received preoperative chemotherapy and radiation and postoperative chemotherapy. Median OS reached 35 mo in cisplatin-irinotecan arm and 5-year OS was 46%, whereas in cisplatin-paclitaxel arm median OS was 21 mo and 5-year OS was 27%. Median PFS was 39.8 mo in cisplatin-irinotecan arm and 12.4 mo in cisplatin-paclitaxel (*P* = 0.046). Investigators decided that there was no significant advantage with the use of any of these two regimens, in comparison to other chemoradiotherapy combinations from other studies[77].

In the randomized, multi-center phase II RTOG 0114 study[78], 78 patients with resected GC were randomized to receive adjuvant chemotherapy with cisplatin-paclitaxel and fluorouracil, or cisplatin-paclitaxel alone. Both arms would receive subsequent chemoradiation with either infusional 5-FU or infusional paclitaxel and 45 Gy of radiation. Rate of grade 3 or higher adverse events was very high in the triplet chemotherapy arm, thus this cohort was terminated early. Patients who received cisplatin-paclitaxel achieved a 2-year DFS of 52%. This study failed to surpass the 67% 2-year DFS from INT0116 study, which was the study's primary endpoint[78].

In the Alliance N0849 randomized phase II trial[79], extended neoadjuvant chemoradiotherapy was compared to standard chemoradiotherapy in patients with locally advanced adenocarcinomas of the esophagus and GEJ. Patients in the extended arm received a combination of docetaxel, oxaliplatin and capecitabine, followed by 5-FU and oxaliplatin concurrently with 50.4 Gy radiation, while patients in the control arm received only chemoradiation. The study’s interim analysis included 42 randomized patients. Among them, 71% had stage III disease and 55% and 40% adenocarcinoma of the esophagus and GEJ, respectively. The primary endpoint was pCR rates, which did not differ significantly between the two arms (33% with extended neoadjuvant therapy and 48% with chemoradiotherapy alone). Rate of grade 4 adverse events was numerically higher in the experimental arm (38% *vs* 24%), although this difference did not reach statistical significance[79].

The phase III CALGB 80101 trial[80] compared two different chemotherapy regimens to be used as part of postoperative chemoradiation treatment plan in patients with gastric or gastroesophageal adenocarcinomas. 546 patients who underwent curative resection were randomized to receive either combination of 5-FU and leucovorin, or postoperative combination of epirubicin, cisplatin and 5-FU, before and after concurrent radiotherapy and 5-FU. 5-year OS was 44% in both arms, with no difference in any subgroups[80].

In the phase II/III PRODIGE5/ACCORD17 trial[81], FOLFOX regimen was compared to combination of cisplatin-5-FU in terms of safety and effectiveness in patients with esophageal carcinoma of various histologies, receiving definitive chemoradiation. 134 patients were randomized to FOLFOX group and 133 to cisplatin-5-FU group. In each group, 85% of patients had squamous histologic type. Median PFS was 9.7 mo in the FOLFOX arm and 9.4 mo in the cisplatin-5-FU arm. One death attributed to toxicity took place in the FOLFOX arm and 6 in the cisplatin-5-FU. Rates of grade 3/4 toxicities were similar between the two cohorts. In general, paresthesia and sensory neuropathy was significantly more common in the FOLFOX arm, while serum creatinine increase and mucositis were significantly more frequent in the cisplatin-5-FU arm[81].

A single arm pilot study by Wo *et al*[82] examined the use of induction FOLFIRINOX before chemoradiation with carboplatin and paclitaxel in patients with locally advanced gastric and gastroesophageal cancer undergoing surgical resection. 25 patients were enrolled, and 20 patients underwent surgical excision and were evaluable for response. At an interim analysis, 37% of the evaluable patients had achieved pCR. Grade 3+ toxicities occurred in 28% of patients. This regimen will be evaluated in further trials[82].

Several chemotherapy regimens have been used adjunct to radiation therapy in the pre- or postoperative setting of gastric and gastroesophageal cancer. The most frequently used is the regimen of carboplatin and paclitaxel from the CROSS study, or the combination of cisplatin and 5-FU. Recent data from the PRODIGE5/ACCORD17 study suggest a clear role for the use of FOLFOX, since it achieved similar results with cisplatin-5-FU with no added toxicity. Triplet regimen of cisplatin, paclitaxel and 5-FU followed by radiation was deemed too toxic in the RTOG 0114 study. Finally, the CALGB 80803 study used a more creative approach, by incorporating intermittent restage with PET-CT and shifting non-responders from FOLFOX or carboplatin, paclitaxel to the other regimen, achieving pCR rates in patients with initially resistant tumors.

***Ongoing clinical trials***

Several ongoing clinical trials attempt to answer clinical questions posed from previous studies or explore novel treatment modalities (Table 5). The multi-center, randomized, phase II CRITICS II trial[83] explores the ideal treatment preoperative modality in patients with resectable GC. Enrolled patients will be randomized in 3 arms, to receive either 4 cycles of neoadjuvant chemotherapy with docetaxel, oxaliplatin and capecitabine, or 2 cycles of DOC followed by chemoradiotherapy with a combination of carboplatin and paclitaxel with 45 Gy radiation, or chemoradiation alone. Primary endpoint is event-free survival at 1 year after randomization, which includes local, regional or distant disease progression and death from any cause[83]. The phase III multicenter, randomized NEO-CRAG trial (NCT01815853) evaluates the safety and efficacy of adding 45 Gy radiation to perioperative chemotherapy with 6 cycles of capecitabine and oxaliplatin (CAPOX) in patients with resectable, locally advanced GC. Similarly, the phase III randomized PREACT study[84] compares preoperative chemotherapy to chemoradiotherapy in patients with locally advanced gastric or GEJ adenocarcinomas, planned to undergo surgical resection. Chemotherapy consists of 3 preoperative cycles of S-1 and oxaliplatin (SOX), while chemoradiation consists of two cycles of SOX and concurrent radiotherapy. Patients in both arms will receive postoperative chemotherapy with 3 cycles of SOX. Primary endpoint is an increase in 3-year DFS with chemoradiotherapy regimen. The study also aims to identify microRNAs as a potential predictive biomarker of response to chemoradiotherapy[84].

A study that attempts to answer different questions with a complex design is ITACA-S2 (NCT01989858). ITACA-S2 is a randomized, multi-center, phase III trial in which patients with operable GC are randomized into 4 arms of different perioperative treatment modalities. Patients in arm A will receive perioperative chemotherapy with three cycles of combination of epirubicin, cisplatin and capecitabine or 5-FU, and will continue the same regimen after surgery. In arm B, patients will receive the same regimen only after gastrectomy. Arms C and D include the same chemotherapy regimens, with the addition of adjuvant chemoradiotherapy with 45 Gy radiation concurrently with 5-FU or capecitabine. The aim of this study is to evaluate the effect of preoperative *vs* postoperative chemotherapy on OS, and also to assess the benefit of postoperative chemoradiotherapy.Finally, the ENRICHED phase III multi-center randomized clinical trial (NCT03680261) compares adjuvant chemotherapy with 6 cycles CAPOX or SOX to adjuvant chemoradiotherapy with 45 Gy radiation concurrently with capecitabine or S-1, followed by 3 cycles of CAPOX or SOX, in patients with resected lymph node positive GC. Primary endpoint of the study is 3-year OS.

Several trials are currently exploring the role of adding concurrent anti-PD1 checkpoint inhibitor pembrolizumab to neoadjuvant chemoradiotherapy in patients with resectable gastric, GEJ and esophageal carcinoma of different histologic types[85] (NCT02730546, NCT03064490, NCT03257163). Furthermore, in a small pilot phase I/II study, addition of combination immunotherapy of nivolumab and ipilimumab to chemoradiation after induction chemotherapy, is being explored in patients with resectable GC (NCT03776487). Newer studies are also focusing on a combination of trimodality treatment and targeting agents, such as the anti-EGFR antibody cetuximab and the VEGFR, EGFR and RET inhibitor vandetanib in the treatment of early GC (NCT00857246, NCT01183559).

Optimization of the radiation component of trimodality treatment is an important part of ongoing trials. NCT04162665 is evaluating magnetic resonance imaging-guided radiotherapy and NCT04523818 the safety and effectiveness of a shorter radiation course in patients with resectable adenocarcinoma (NCT04523818). In the Danish CURE study[86], ctDNA is being used as a predictive biomarker to response and disease progression after different treatment modalities, including chemoradiation in patients with gastroesophageal cancer (NCT04576858). A phase II trial still in recruitment is exploring the role of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy during diagnostic laparoscopy, followed by neoadjuvant chemoradiation, for locally advanced GC (NCT04308837).

Combination of different treatment modalities is an ongoing research field in early gastric cancer, due to sub-optimal results of the current standard of care. Many phase III studies such as TOPGEAR, CRITICS II, NEO-CRAG and PREACT will offer concrete data on whether addition of radiation therapy to the newest preoperative chemotherapy regimens, such as FLOT, impacts clinical outcomes. ITACA-S2 is a multi-arm comprehensive study evaluating both the ideal regimen and timing of perioperative treatment, while the ENRICHED trial repeats the adjuvant chemoradiation design in a modern setting. Finally, a significant number of trials incorporated different checkpoint inhibitors in the preoperative setting, after the success of Checkmate 577.

**CONCLUSION**

Complete surgical resection of the tumor provides the best chance for cure; however, a significant proportion of patients presents with unresectable disease. Adjunctive therapy besides gastrectomy is recommended in a multidisciplinary approach and preoperative therapy is the cornerstone of management in the West. The evidence-based approach should include perioperative chemotherapy or postoperative chemoradiotherapy for selected patients. Similarly, for resectable GEJ cancers, preoperative chemoradiotherapy will enhance surgical outcomes and improve the pCR rate. Evidence from the ARTIST 2 and CRITICS study do not support the adjuvant use of radiation therapy in adequately resected tumors. In the preoperative setting, although prospective data comparing neoadjuvant chemotherapy to chemoradiotherapy are still immature, there is a trend to improved local control and pCR rates, which may translate into significant clinical outcomes in the future. Long term results from the Neo-AEGIS and TOPGEAR trial are eagerly awaited. Moreover, future research should also focus is on optimizing the chemotherapy regimen, defining the role of radiotherapy and immunotherapy and exploring the effect of treatment timing (preoperative, postoperative or both).

**REFERENCES**

1 **Jemal A**, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 1893-1907 [PMID: 20647400 DOI: 10.1158/1055-9965.EPI-10-0437]

2 **Karimi P**, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. *Cancer Epidemiol Biomarkers Prev* 2014; **23**: 700-713 [PMID: 24618998 DOI: 10.1158/1055-9965.EPI-13-1057]

3 **Then EO**, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A, Gaduputi V. Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis. World J Oncol 2020; 11(2): 55-64 [PMID: 32284773 PMCID: PMC7141161 DOI: 10.14740/wjon1254]

4 **Charalampakis N**, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. *Cancer Med* 2018; **7**: 123-133 [PMID: 29239137 DOI: 10.1002/cam4.1274]

5 **Dicken BJ**, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. *Ann Surg* 2005; **241**: 27-39 [PMID: 15621988 DOI: 10.1097/01.sla.0000149300.28588.23]

6 **Ma J**, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in gastric cancer. *Oncol Lett* 2016; **11**: 2959-2964 [PMID: 27123046 DOI: 10.3892/ol.2016.4337]

7 **Hansford S**, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Santos TA, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, Oliveira C, Pharoah PD, Huntsman DG. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. *JAMA Oncol* 2015; **1**: 23-32 [PMID: 26182300 DOI: 10.1001/jamaoncol.2014.168]

8 **Rice TW**, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. *Ann Cardiothorac Surg* 2017; **6**: 119-130 [PMID: 28447000 DOI: 10.21037/acs.2017.03.14]

9 **Cancer Genome Atlas Research Network**; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre; Harvard Medical School; Institute for Systems Biology; KU Leuven; Mayo Clinic; Memorial Sloan Kettering Cancer Center; National Cancer Institute; Nationwide Children’s Hospital; Stanford University; University of Alabama; University of Michigan; University of North Carolina; University of Pittsburgh; University of Rochester; University of Southern California; University of Texas MD Anderson Cancer Center; University of Washington; Van Andel Research Institute; Vanderbilt University; Washington University; Genome Sequencing Center: Broad Institute; Washington University in St. Louis; Genome Characterization Centers: BC Cancer Agency; Broad Institute; Harvard Medical School; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of North Carolina; University of Southern California Epigenome Center; University of Texas MD Anderson Cancer Center; Van Andel Research Institute; Genome Data Analysis Centers: Broad Institute; Brown University:; Harvard Medical School; Institute for Systems Biology; Memorial Sloan Kettering Cancer Center; University of California Santa Cruz; University of Texas MD Anderson Cancer Center; Biospecimen Core Resource: International Genomics Consortium; Research Institute at Nationwide Children’s Hospital; Tissue Source Sites: Analytic Biologic Services; Asan Medical Center; Asterand Bioscience; Barretos Cancer Hospital; BioreclamationIVT; Botkin Municipal Clinic; Chonnam National University Medical School; Christiana Care Health System; Cureline; Duke University; Emory University; Erasmus University; Indiana University School of Medicine; Institute of Oncology of Moldova; International Genomics Consortium; Invidumed; Israelitisches Krankenhaus Hamburg; Keimyung University School of Medicine; Memorial Sloan Kettering Cancer Center; National Cancer Center Goyang; Ontario Tumour Bank; Peter MacCallum Cancer Centre; Pusan National University Medical School; Ribeirão Preto Medical School; St. Joseph’s Hospital &Medical Center; St. Petersburg Academic University; Tayside Tissue Bank; University of Dundee; University of Kansas Medical Center; University of Michigan; University of North Carolina at Chapel Hill; University of Pittsburgh School of Medicine; University of Texas MD Anderson Cancer Center; Disease Working Group: Duke University; Memorial Sloan Kettering Cancer Center; National Cancer Institute; University of Texas MD Anderson Cancer Center; Yonsei University College of Medicine; Data Coordination Center: CSRA Inc; Project Team: National Institutes of Health. Integrated genomic characterization of oesophageal carcinoma. *Nature* 2017; **541**: 169-175 [PMID: 28052061 DOI: 10.1038/nature20805]

10 **Mariette C**, Finzi L, Piessen G, Van Seuningen I, Triboulet JP. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. *World J Surg* 2005; **29**: 39-45 [PMID: 15599738 DOI: 10.1007/s00268-004-7542-x]

11 **Siewert JR**, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? *Semin Radiat Oncol* 2007; **17**: 38-44 [PMID: 17185196 DOI: 10.1016/j.semradonc.2006.09.007]

12 **Domper Arnal MJ**, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. *World J Gastroenterol* 2015; **21**: 7933-7943 [PMID: 26185366 DOI: 10.3748/wjg.v21.i26.7933]

13 **Berry MF**. Esophageal cancer: staging system and guidelines for staging and treatment. *J Thorac Dis* 2014; **6 Suppl 3**: S289-S297 [PMID: 24876933 DOI: 10.3978/j.issn.2072-1439.2014.03.11]

14 **Coleman HG**, Xie SH, Lagergren J. The Epidemiology of Esophageal Adenocarcinoma. *Gastroenterology* 2018; **154**: 390-405 [PMID: 28780073 DOI: 10.1053/j.gastro.2017.07.046]

15 **Jain S**, Dhingra S. Pathology of esophageal cancer and Barrett's esophagus. *Ann Cardiothorac Surg* 2017; **6**: 99-109 [PMID: 28446998 DOI: 10.21037/acs.2017.03.06]

16 **Ignatova E**, Seriak D, Fedyanin M, Tryakin A, Pokataev I, Menshikova S, Vakhabova Y, Smirnova K, Tjulandin S, Ajani JA. Epstein-Barr virus-associated gastric cancer: disease that requires special approach. *Gastric Cancer* 2020; **23**: 951-960 [PMID: 32514646 DOI: 10.1007/s10120-020-01095-z]

17 **Sohn BH**, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, Ajani JA, Lee JS. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. *Clin Cancer Res* 2017; **23**: 4441-4449 [PMID: 28747339 DOI: 10.1158/1078-0432.CCR-16-2211]

18 **Kim ST**, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nat Med* 2018; **24**: 1449-1458 [PMID: 30013197 DOI: 10.1038/s41591-018-0101-z]

19 **Cancer Genome Atlas Research Network**. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; **513**: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]

20 **Tokunaga M**, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, Kinugasa Y. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. *Surg Today* 2020; **50**: 30-37 [PMID: 31612329 DOI: 10.1007/s00595-019-01896-5]

21 **Choi AH**, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. *World J Gastroenterol* 2015; **21**: 7343-7348 [PMID: 26139980 DOI: 10.3748/wjg.v21.i24.7343]

22 **Li Y**, Wang J, Ma X, Tan L, Yan Y, Xue C, Hui B, Liu R, Ma H, Ren J. A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. *Int J Biol Sci* 2016; **12**: 1022-1031 [PMID: 27489505 DOI: 10.7150/ijbs.15438]

23 **Kaltenmeier C**, Althans A, Mascara M, Nassour I, Khan S, Hoehn R, Zureikat A, Tohme S. Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes. *Am Surg* 2021; **87**: 1145-1154 [PMID: 33342268 DOI: 10.1177/0003134820972083]

24 **Xiang M**, Chang DT, Heestand GM, Pollom EL. Survival after neoadjuvant approaches to gastroesophageal junction cancer. *Gastric Cancer* 2020; **23**: 175-183 [PMID: 31230228 DOI: 10.1007/s10120-019-00980-6]

25 **Siewert JR**, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. *Br J Surg* 1998; **85**: 1457-1459 [PMID: 9823902 DOI: 10.1046/j.1365-2168.1998.00940.x]

26 **Johnston FM**, Beckman M. Updates on Management of Gastric Cancer. *Curr Oncol Rep* 2019; **21**: 67 [PMID: 31236716 DOI: 10.1007/s11912-019-0820-4]

27 **Weledji EP**. The principles of the surgical management of gastric cancer. *Int J Surg Oncol (N Y)* 2017; **2**: e11 [PMID: 29177225 DOI: 10.1097/IJ9.0000000000000011]

28 **Baskar R**, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. *Int J Med Sci* 2012; **9**: 193-199 [PMID: 22408567 DOI: 10.7150/ijms.3635]

29 **Tey J**, Soon YY, Koh WY, Leong CN, Choo BA, Ho F, Vellayappan B, Lim K, Tham IW. Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. *Oncotarget* 2017; **8**: 25797-25805 [PMID: 28445941 DOI: 10.18632/oncotarget.15554]

30 **Hennequin C**, Guillerm S, Quero L. Combination of chemotherapy and radiotherapy: A thirty years evolution. *Cancer Radiother* 2019; **23**: 662-665 [PMID: 31473087 DOI: 10.1016/j.canrad.2019.07.157]

31 **Curran WJ Jr**, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst* 2011; **103**: 1452-1460 [PMID: 21903745 DOI: 10.1093/jnci/djr325]

32 **Lawrence TS**, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. *Semin Radiat Oncol* 2003; **13**: 13-21 [PMID: 12520460 DOI: 10.1053/srao.2003.50002]

33 **Hirata E**, Sahai E. Tumor Microenvironment and Differential Responses to Therapy. *Cold Spring Harb Perspect Med* 2017; **7** [PMID: 28213438 DOI: 10.1101/cshperspect.a026781]

34 **Vellayappan BA**, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. *Cochrane Database Syst Rev* 2017; **8**: CD010511 [PMID: 28829911 DOI: 10.1002/14651858.CD010511.pub2]

35 **Sharabi AB**, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. *Lancet Oncol* 2015; **16**: e498-e509 [PMID: 26433823 DOI: 10.1016/S1470-2045(15)00007-8]

36 **Deng L**, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. *J Clin Invest* 2014; **124**: 687-695 [PMID: 24382348 DOI: 10.1172/JCI67313]

37 **Macdonald JS**, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001; **345**: 725-730 [PMID: 11547741 DOI: 10.1056/NEJMoa010187]

38 **McNamara MJ**, Adelstein DJ, Bodmann JW, Greskovich JF Jr, Ives DI, Mason DP, Murthy SC, Rice TW, Saxton JP, Sohal D, Stephans K, Rodriguez CP, Videtic GM, Rybicki LA. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction. *J Thorac Oncol* 2014; **9**: 1561-1567 [PMID: 25170643 DOI: 10.1097/JTO.0000000000000312]

39 **Adelstein DJ**, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, Mason DP, Rodriguez CP, Ives DI. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. *J Thorac Oncol* 2009; **4**: 1264-1269 [PMID: 19668013 DOI: 10.1097/JTO.0b013e3181b26f8e]

40 **Mansouri H**, Zemni I, Achouri L, Mahjoub N, Ayedi MA, Ben Safta I, Ben Dhiab T, Chargui R, Rahal K. Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: should we use selection criteria? *Rep Pract Oncol Radiother* 2021; **26**(2): 266-280 [PMID: 34211778 PMCID: PMC8241305 DOI: 10.5603/RPOR.a2021.0040]

41 **Yekeduz E**, Dogan I, Akbulut H, Karabulut S, Utkan G, Urun Y. A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients. *J Clin Oncol* 2021; **39**: 185 [DOI: 10.1200/JCO.2021.39.3\_suppl.185]

42 **Xie C**, Jin X, Chen D. Capecitabine plus oxaliplatin vs capecitabine plus oxaliplatin with concurrent radiotherapy in the treatment of gastric cancer after D2 gastrectomy. *J Clin Oncol* 2018; **36**: 4059 [DOI: 10.1200/JCO.2018.36.15\_suppl.4059]

43 **Wang MJ**, Li C, Sun Y, Shen FJ, Wang CB. Prognostic effect of adjuvant chemoradiotherapy for patients with gastric cancer: an updated evidence of randomized controlled trials. Oncotarget 2017; 8(61): 102880-102887 [PMID: 29262530 PMCID: PMC5732696 DOI: 10.18632/oncotarget.21983]

44 **Cats A**, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. *Lancet Oncol* 2018; **19**: 616-628 [PMID: 29650363 DOI: 10.1016/S1470-2045(18)30132-3]

45 **Park SH**, Lee J, Sohn TS, Lim DH, Kim K-M, An JY, Choi MG, Lee JH, Bae JM, Kim S, Lee SJ, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial. Precis Future Med 2019; 3(1): 24-29 [DOI: 10.23838/pfm.2018.00177]

46 **Park SH**, Zang DY, Han B, Ji JH, Kim TG, Oh SY, Hwang IG, Kim JH, Shin D, Lim DH, Kim KM, An JY, Choi M-G, Lee J-H, Sohn TS, Bae J-M, Kim S, Kim S, Lee J, Kang WK. ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). *J Clin Oncol* 2019; **37**: 4001 [DOI: 10.1200/JCO.2019.37.15\_suppl.4001]

47 **Rivera F**, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E; Spanish Cooperative Group for Digestive Tumor Therapy. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2009; **75**: 1430-1436 [PMID: 19540072 DOI: 10.1016/j.ijrobp.2008.12.087]

48 **Ludmir EB**, Das P. Shifting sands: the role of radiotherapy for patients with gastric and gastroesophageal adenocarcinoma. Transl Gastroenterol Hepatol 2021; 6: 50 [PMID: 34423171 PMCID: PMC8343419 DOI: 10.21037/tgh.2020.03.01]

49 **Turgeman I**, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021; 9(10): 903 [PMID: 34164537 PMCID: PMC8184467 DOI: 10.21037/atm.2020.03.110]

50 **Ilson DH**, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. *Cancer* 2012; **118**: 2820-2827 [PMID: 21990000 DOI: 10.1002/cncr.26591]

51 **van der Wilk BJ**, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens J, Wijnhoven BPL, van Lanschot JJB. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis 2019; 11(Suppl 5): S621-S631 [PMID: 31080638 PMCID: PMC6503275 DOI: 10.21037/jtd.2018.11.143]

52 **Stahl M**, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, Wilke H, Budach W. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. *Eur J Cancer* 2017; **81**: 183-190 [PMID: 28628843 DOI: 10.1016/j.ejca.2017.04.027]

53 **Ma Z**, Yuan M, Bao Y, Wang Y, Men Y, Hui Z. Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis. Front Oncol 2021; 11: 728185 [PMID: 34745950 PMCID: PMC8564474 DOI: 10.3389/fonc.2021.728185]

54 **von Döbeln GA**, Klevebro F, Jacobsen AB, Johannessen HO, Nielsen NH, Johnsen G, Hatlevoll I, Glenjen NI, Friesland S, Lundell L, Yu J, Nilsson M. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. *Dis Esophagus* 2019; **32** [PMID: 30137281 DOI: 10.1093/dote/doy078]

55 **Zhao X**, Ren Y, Hu Y, Cui N, Wang X, Cui Y. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials. *PLoS One* 2018; **13**: e0202185 [PMID: 30138325 DOI: 10.1371/journal.pone.0202185]

56 **Hou S**, Pan Z, Hao X, Hang Q, Ding Y. Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer. *Cancers (Basel)* 2021; **13(20)** [PMID: 34680311 PMCID: PMC8533976 DOI: 10.3390/cancers13205162]

57 **van Hagen P**, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012; **366**: 2074-2084 [PMID: 22646630 DOI: 10.1056/NEJMoa1112088]

58 **Cunningham D**, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006; **355**: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]

59 **Al-Batran SE**, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019; **393**: 1948-1957 [PMID: 30982686 DOI: 10.1016/S0140-6736(18)32557-1]

60 **Reynolds JV**, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Roy R, Falk S, Hanna G, Bartlett FR, Parker I, Alvarez-Iglesias A, Nilsson M, Piessen G, Risum S, Ravi N, McDermott RS. Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452). *J Clin Oncol* 2021; **39**: 4004 [DOI: 10.1200/JCO.2021.39.15\_suppl.4004]

61 **Leong T**, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O'Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G, Simes J, Wong R. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. *Ann Surg Oncol* 2017; **24**: 2252-2258 [PMID: 28337660 DOI: 10.1245/s10434-017-5830-6]

62 **Pape M**, Vissers PAJ, Beerepoot L, Van Berge Henegouwen MI, Lagarde S, Mook S, Bertwistle D, McDonald L, Van Laarhoven HWM, Verhoeven R. Disease-free and overall survival in nonmetastatic esophageal or gastroesophageal junctional cancer after treatment with curative intent: A nationwide population-based study. *J Clin Oncol* 2021; **39**: 246 [DOI: 10.1200/JCO.2021.39.3\_suppl.246]

63 **Tim Spencer**, Jonathan Helbrow, Eleanor Pilsworth, Stephen Falk, Helen Winter, Thomas Bird. Selecting the optimal neoadjuvant treatment approach based on the risk of an involved surgical margin in locally advanced adenocarcinoma of the esophagus and esophagogastric junction. *J Clin Oncol* 2021; **39**: 198 [DOI: 10.1200/JCO.2021.39.3\_suppl.198]

64 **Jurkowski L**, Shreenivas AV, Chakrabarti S, Kamgar M, Thomas JP, Puckett L, Shukla M, Gore E, Evans J, Johnstone CA, Gasparri M, Linsky P, Johnstone D, Dua K, Khan AH, Madhavan S, Szabo A, George B. Association of total neoadjuvant therapy with favorable clinical outcomes in patients with locally advanced esophageal and gastroesophageal junction adenocarcinomas (LA-GEJ CA). *J Clin Oncol* 2021; **39**: 231 [DOI: 10.1200/JCO.2021.39.3\_suppl.231]

65 **Schizas D**, Charalampakis N, Kole C, Mylonas KS, Katsaros I, Zhao M, Ajani JA, Psyrri A, Karamouzis MV, Liakakos T. Immunotherapy for esophageal cancer: a 2019 update. *Immunotherapy* 2020; **12**: 203-218 [PMID: 32208794 DOI: 10.2217/imt-2019-0153]

66 **Kelly RJ**, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano JL, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zhang J, Zhu L, Lei M, Kondo K, Cleary JM, Moehler M. LBA9\_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. *Ann Oncol* 2020; **31**: S1193-S1194 [DOI: 10.1016/j.annonc.2020.08.2299]

67 **Ku GY**, Abraham Jing-Ching Wu, Smita Sihag, Bernard J. Park, David Randolph Jones, Ping Gu, Steven Brad Maron, Ryan Sugarman, Sree Bhavani Chalasani, Marina Shcherba, Lara Feder, Kendall Cowie, Jaclyn Norris, Valerie Johnson, Laura H. Tang, David H. Ilson, Yelena Y. Janjigian, Daniela Molena. Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma. *J Clin Oncol* 2021; **39**: 226 [DOI: 10.1200/JCO.2021.39.3\_suppl.226]

68 **Goodman KA**, Hall N, Bekaii-Saab TS, Ou F-S, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Perry K, Frankel WL, Venook AP, O'Reilly EM, Ilson DH. Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. *J Clin Oncol* 2018; **36**: 4012 [DOI: 10.1200/JCO.2018.36.15\_suppl.4012]

69 **Safran H**, Winter KA, Wigle DA, DiPetrillo TA, Haddock MG, Hong TS, Leichman LP, Rajdev L, Resnick MB, Kachnic LA, Seaward SA, Mamon HJ, Pardo DAD, Anderson CM, Shen X, Sharma AK, Katz AW, Salo JC, Leonard KL, Crane CH. Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. *J Clin Oncol* 2020; **38**: 4500 [DOI: 10.1200/JCO.2020.38.15\_suppl.4500]

70 **Abali H**, Yalcin S, Onal C, Dane F, Oksuzoglu B, Ozdemir N, Mertsoylu H, Artac M, Camci C, Karabulut B, Basal FB, Budakoglu B, Sendur MAN, Goktas B, Ozdener F, Baygul A. A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+ gastric or gastroesophageal junction cancer (TOXAG study). *J Clin Oncol* 2018; **36**: 26 [DOI: 10.1200/JCO.2018.36.4\_suppl.26]

71 **Ruhstaller T**, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A, Plasswilm L, Budach W, Eisterer W, Hawle H, Mariette C, Hess V, Mingrone W, Montemurro M, Girschikofsky M, Schmidt SC, Bitzer M, Bedenne L, Brauchli P, Stahl M. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). *Ann Oncol* 2018; **29**: 1386-1393 [DOI: 10.1093/annonc/mdy105]

72 **Ku GY**, Bains MS, Park DJ, Janjigian YY, Rusch VW, Rizk NP, Yoon SS, Millang B, Capanu M, Goodman KA, Ilson DH. Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. *J Gastrointest Oncol* 2016; **7**: 828-837 [PMID: 28078107 DOI: 10.21037/jgo.2016.08.09]

73 **Jiang DM**, Sim HW, Espin-Garcia O, Chan BA, Natori A, Lim CH, Moignard S, Chen EX, Liu G, Darling G, Swallow CJ, Brar S, Brierley J, Ringash J, Wong R, Kim J, Rogalla P, Hafezi-Bakhtiari S, Knox JJ, Jang RW, Elimova E. Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer. *Oncology* 2021; **99**: 49-56 [PMID: 33053548 DOI: 10.1159/000510446]

74 **Chakravarthy AB**, Catalano PJ, Mondschein JK, Rosenthal DI, Haller DG, Whittington R, Spitz FR, Wagner H, Sigurdson ER, Tschetter LK, Bayer GK, Mulcahy MF, Benson AB. Phase II Trial of Paclitaxel/Cisplatin Followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/Leucovorin for Gastric Cancer (ECOG E7296). *Gastrointest Cancer Res* 2012; **5**: 191-197 [PMID: 23293700]

75 **Goodman KA**, Niedzwiecki D, Hall N, Bekaii-Saab TS, Ye X, Meyers MO, Mitchell-Richards K, Boffa DJ, Frankel WL, Venook AP, Hochster HS, Crane CH, O'Reilly EM, Ilson DH. Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. *J Clin Oncol* 2017; **35**: 1 [DOI: 10.1200/JCO.2017.35.4\_suppl.1]

76 **Zhao Z**, Yang S, Zhou A, Li X, Fang R, Zhang S, Zhao G, Li P. Small Extracellular Vesicles in the Development, Diagnosis, and Possible Therapeutic Application of Esophageal Squamous Cell Carcinoma. Front Oncol 2021; **11**: 732702 [PMID: 34527593 PMCID: PMC8435888 DOI: 10.3389/fonc.2021.732702]

77 **Kleinberg LR**, Catalano PJ, Forastiere AA, Keller SM, Mitchel EP, Anne PR, Benson AB 3rd. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. *Int J Radiat Oncol Biol Phys* 2016; **94**: 738-746 [PMID: 26972646 DOI: 10.1016/j.ijrobp.2015.12.009]

78 **Schernberg A**, Rivin Del Campo E, Rousseau B, Matzinger O, Loi M, Maingon P, Huguet F. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clin Transl Radiat Oncol 2018; 10: 13-22 [PMID: 29928701 PMCID: PMC6008627 DOI: 10.1016/j.ctro.2018.02.005]

79 **Alberts SR**, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Wu T-T, Yoon HH, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP. Randomized phase II trial of extended vs standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849. *J Clin Oncol* 2013; **31**: 4026 [DOI: 10.1200/JCO.2013.31.15\_suppl.4026]

80 **Wu L**, Feng Y, Wu Z, Xu H, Zhang C, Ning J, Wang R, Chen J, Xie M, Zhang Y, Bu L, Hao J, Ma T. Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis. *World J Surg Oncol* 2021; **19**(1): 272 [PMID: 34507562 PMCID: PMC8434742 DOI: 10.1186/s12957-021-02390-4]

81 **Conroy T**, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014; **15**: 305-314 [PMID: 24556041 DOI: 10.1016/S1470-2045(14)70028-2]

82 **Wo JY-L**, Clark JW, Allen JN, Blaszkowsky LS, Keane F, Drapek LC, Ryan DP, Corcoran RB, Roeland E, Parikh AR, Khandekar MJ, Heist RS, Morse C, Yeap BY, Ulysse CA, Christopher B, Lanuti M, Berger DL, Mullen JT, Hong TS. A pilot study of neoadjuvant FOLFIRINOX followed by chemoradiation for gastric and gastroesophageal cancer: Preliminary results. *J Clin Oncol* 2019; **37**: 4057 [DOI: 10.1200/JCO.2019.37.15\_suppl.4057]

83 **Slagter AE**, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. *BMC Cancer* 2018; **18**: 877 [PMID: 30200910 DOI: 10.1186/s12885-018-4770-2]

84 **Liu X**, Cai H, Sheng W, Huang H, Long Z, Wang Y. microRNAs expression profile related with response to preoperative radiochemotherapy in patients with locally advanced gastric cancer. *BMC Cancer* 2018; **18**: 1048 [PMID: 30373600 DOI: 10.1186/s12885-018-4967-4]

85 **Hsu CH**, Guo JC, Huang TC, Kuo HY, Lin CC, Hsu FM, Cheng JC, Huang PM, Lee JM. Phase II study of pembrolizumab after chemoradiotherapy (CRT) as adjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients at high risk of recurrence following preoperative CRT plus surgery. *J Clin Oncol* 2021; **39**: [DOI: 10.1200/JCO.2021.39.3\_suppl.TPS259]

86 **Lumish MA**, Tarazona N, Janjigian YY. Postoperative ctDNA monitoring: a canary in a coalmine. *Ann Oncol* 2021; **32**: 431-433 [PMID: 33484835 DOI: 10.1016/j.annonc.2021.01.005]

87 **McNamara MJ**, Rice TW, Rybicki LA, Rodriguez CP, Videtic GMM, Saxton JP, Stephans KL, Greskovich J, Sohal D, Mason DP, Murthy SC, Ives DI, Bodmann J, Adelstein DJ. A phase II trial of induction epirubicin, oxaliplatin, and flourouracil, surgery and post-operative concurrent cisplatin and fluorouracil chemoradiotherapy (CRT) in patients (pts) with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). *J Clin Oncol* 2013; **31**: 4087 [DOI: 10.1200/JCO.2013.31.15\_suppl.4087]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflict of interest related to the manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American Society of Clinical Oncology; European Society for Medical Oncology.

**Peer-review started:** March 25, 2021

**First decision:** June 16, 2021

**Article in press:** December 10, 2021

**Specialty type:** Oncology

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Chen SY, Chisthi MM, Fu T, Song L **S-Editor:** Zhang H **L-Editor:** A **P-Editor:** Zhang H

**Table 1 Postoperative chemoradiation clinical trials**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study name/phase** | **Size/stage/primary tumor location/histology** | **Intervention** | **Primary endpoint** |
| INT-0116/phase III[37] | 556 patients, IB-IVM0/stomach/adenocarcinoma | Gastrectomy D0-2 (both arms) AND E: 5-FU/LV + 45Gy radiation OR C: No post-surgical treatment | mOS: 27 m control *vs* 36 m experimental, HR: 1.35 (95% CI: 1.09-1.66, *P* = 0.005) |
| McNamara *et al*[87]/phase II | 60 patients/T3-4/N1/M1a/esophagus/22% GEJ 78%/adenocarcinoma | Induction epirubicin, oxaliplatin, 5-FU → gastrectomy → E: adjuvant concurrent cisplatin, 5-FU + 50 to 55 Gy radiation | Surgical resection: 90% underwent surgical resection |
| Adelstein *et al*[39]/phase II | 50 patients/T3/N1/M1a/esophagus/ 28% GEJ 72% adenocarcinoma 86% SCC 14% | Gastrectomy → E: cisplatin, 5-FU + 50.4-59.4 Gy radiation | OS rate: 51% 4-yr OS rate |
| Xie *et al*[42]/phase III | 144 patients/T3-4/N1-3/stomach/adenocarcinoma | Gastrectomy D2 (both arms) AND E: capecitabine, oxaliplatin, 45 Gy radiation OR C: capecitabine, oxaliplatin | DFS rate: 72.8% experimental *vs* 76.3% control 3-yr DFS rate (*P* = 0.868) |
| ARTIST/phase III[43] | 458 patients, IB-IV/stomach/adenocarcinoma (39% intestinal, 57% diffuse) | Gastrectomy D2 (both arms) AND E: capecitabine, cisplatin + 45 Gy radiation OR C: capecitabine, cisplatin | DFS rate: 78% experimental *vs* 74% control 3-yr DFS rate *P* = 0.0862 |
| CRITICS/phase III[44] | 788 patients/IΒ-IVA/stomach/ 83% GEJ 17% adenocarcinoma (32% intestinal 30% diffuse) | Preoperative epirubicin, cisplatin or oxaliplatin, capecitabine → Gastrectomy D1 (both arms) AND E: epirubicin, cisplatin or oxaliplatin, capecitabine or 5-FU + 45 Gy radiation OR C: epirubicin, cisplatin or oxaliplatin, capecitabine or 5-FU | mOS: 43 m control *vs* 37m experimental HR 1.01 (95%CI: 0.84-1.22; *P* = 0.90) |
| ARTIST 2/phase III[46] | 538 patients/II/III N+/stomach/adenocarcinoma | Gastrectomy D2 (both arms) AND E1: S-1, oxaliplatin, + 45 Gy radiation OR E2: S-1, oxaliplatin ΟR C: S-1 | DFS rate: 65% control, 78% experimental 2, 73% experimental 1 3-yr DFS rate experimental 2 *vs* experimental 1 HR 0.910, (*P* = 0.667) |

mOS: Median overall survival; mDFS: Median disease-free survival; mPFS: Median progression-free survival; E: Experimental; C: Control; HR: Hazard ratio; 5-FU: 5-fluorouracil; LV: Leucovorin; Gy: Gray; S-1: Tegafur/gimeracil/oteracil; pCR: Pathologic complete response; GEJ: Gastroesophageal junction; CRT: Chemoradiation; AEG: Adenocarcinomas of the esophagogastric junction.

**Table 2 Preoperative chemoradiation clinical trials**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study name/phase** | **Size/stage/primary tumor location/histology** | **Intervention** | **Primary endpoint** |
| Rivera *et al*[47]/phase II | 23 patients/II-IV, M0/stomach/57% GEJ 43% adenocarcinoma | Irinotecan, cisplatin + 45 Gy radiation → surgery | pCR: 2/23 (9%) achieved pCR after CRT |
| RTOG 9904/phase II[48] | 43 patients/IB-III/stomach/adenocarcinoma | Cisplatin, 5-FU/LV + 45 Gy radiation → gastrectomy | pCR: 26% achieved pCR |
| S0356/phase II[49] | 93 patients/II-III/esophagus/60% GEJ 40% adenocarcinoma | Oxaliplatin, 5-FU + 45 Gy radiation → surgery | pCR: 28% achieved pCR |
| Ilson *et al*[50]/phase II | 55 patients/uT1N1M0-uT2-4NanyM0/esophagus 67% GEJ 33%/adenocarcinoma 75% SCC 22% | Cisplatin, irinotecan + 50.4 Gy radiation → surgery | pCR: 16% achieved pCR |
| Ajani *et al*[51]/phase II | 126 patients/II-III/esophagus 3.2% GEJ 96.8% (AEG1 64.3%, AEG2 32.5%)/adenocarcinoma 96.8% SCC 3.2% | E: induction oxaliplatin, 5-FU OR C: no induction chemotherapy AND oxaliplatin, 5-FU + 50.4 Gy radiation → surgery (both arms) | pCR: 13% control *vs* 26% experimental (*P* = 0.094) |
| NeoRes/phase II[54] | 181 patients/T1-3, Nany (except T1N0)/esophagus 82% GEJ 18%/adenocarcinoma 72% SCC 28% | E: cisplatin, 5-FU + 40 Gy radiation OR C: cisplatin, 5-FUAND surgery (both arms) | pCR: 28% experimental *vs* 9% control |
| CALGB 9781/phase III[56] | 56 patients/T1-3Nany/esophagus/ GEJ adenocarcinoma 75% SCC 25% | E: cisplatin, 5-FU + 50.4 Gy radiation OR C: no preoperative treatment AND surgery (both arms) | mOS: 4.48 y experimental *vs* 1.79 y control (*P* = 0.002) |
| POET/phase III[52] | 119 patients/T3-4/GEJ/adenocarcinoma | E: induction cisplatin, 5-FU/LV → cisplatin, etoposide + 30 Gy radiation OR C: cisplatin, 5-FU/LV AND surgery | OS rate: 46.7% experimental *vs* 26.1% control 3-yr OS HR 0.65, (95%CI: 0.42-1.01, *P* = 0.055) |
| CROSS/phase III[57] | 366 patients/T1N1, T2-3N0-1/esophagus 73.2% GEJ 24%/adenocarcinoma 75% SCC 23% | E: carboplatin, paclitaxel + 41.4 Gy radiation OR C: no chemoradiation AND surgery (both arms) | mOS: 49.4 m experimental *vs* 24 m control HR 0.657, (95%CI: 0.495-0.871, *P* = 0.003) |
| Neo-AEGIS/phase III[60] | 377/cT2-3N0-3M0/esophagus GEJ/adenocarcinoma | E: carboplatin, paclitaxel + 41.4 Gy radiation OR C: epirubicin, cisplatin/oxaliplatin, 5-FU/capecitabine or docetaxel, oxaliplatin, leucovorin, 5-FU AND surgery (all arms) | OS rate: 56% experimental *vs* 57% 3-yr OS HR 1.02, (95%CI: 0.74-1.42) |

mOS: Median overall survival; mDFS: Median disease-free survival; mPFS: Median progression-free survival; E: Experimental; C: Control; HR: Hazard ratio; 5-FU: 5-fluorouracil; LV: Leucovorin; Gy: Gray; S-1: Tegafur/gimeracil/oteracil; pCR: Pathologic complete response; GEJ: Gastroesophageal junction; CRT: Chemoradiation; AEG: Adenocarcinomas of the esophagogastric junction.

**Table 3 Chemoradiation and targeted therapies clinical trials**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study name/phase** | **Size/stage/primary tumor location/histology** | **Intervention** | **Primary endpoint** |
| Ku *et al*[72]/phase II | 33 patients/uT2-3N0-1/esophagus 33% GEJ 66%/adenocarcinoma | E: cisplatin, irinotecan + bevacizumab + 50.4 Gy radiation → surgery | Tolerability: 59% grade 3/4 hematologic toxicity 42% grade 3/4 non-hematologic toxicity (including deep vein thrombosis) |
| TOXAG/phase II[70] | 34 patients/76% > IIIA/stomach GEJ/adenocarcinoma HER2 positive | E: gastrectomy D2 → oxaliplatin, capecitabine + 45 Gy radiation + trastuzumab | Tolerability: 90.3% completed 3 cycles of treatment |
| SAKK 75/08/phase III[71] | 300 patients/T2N1-3, T3Nany, T4aNany/esophagus 50% GEJ 50%/adenocarcinoma 64% SCC 36% | E: docetaxel, cisplatin + 45 Gy radiation + cetuximab → surgery → cetuximab OR C: docetaxel, cisplatin + 45 Gy radiation AND surgery (both arms) | mPFS: 2.9 y experimental *vs* 2 y control HR 0.79; (95%CI: 0.58 to 1.07, *P* = 0.13) |
| RTOG 1010/phase III[69] | 203 patients/T1N1-2, T2-3N0-2/esophagus GEJ/adenocarcinoma HER2 positive | E: carboplatin, paclitaxel + 50.4 Gy radiation + trastuzumab → surgery → trastuzumab OR  C: carboplatin, paclitaxel + 50.4Gy radiation → Surgery | mDFS: 19.6 m experimental *vs* 14.2 control HR 0.97 (95%CI: 0.69-1.36) |
| CheckMate 577/phase III[66] | 794 patients/II-III, ≥ ypT1 or ≥ ypN1/esophagus 60% GEJ 40%/adenocarcinoma 71% SCC 29% | Neoadjuvant chemoradiation → surgery (both arms) AND E: nivolumab OR C: placebo | mDFS: 22.4 m experimental *vs* 11 m control HR 0.69 (95%CI: 0.56-0.86, *P* = 0.0003) |

mOS: Median overall survival; mDFS: Median disease-free survival; mPFS: Median progression-free survival; E: Experimental; C: Control; HR: Hazard ratio; 5-FU: 5-fluorouracil; LV: Leucovorin; Gy: Gray; S-1: Tegafur/gimeracil/oteracil; pCR: Pathologic complete response; GEJ: Gastroesophageal junction; CRT: Chemoradiation; AEG: Adenocarcinomas of the esophagogastric junction.

**Table 4 Clinical trials comparing chemotherapy regimens**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study name/phase** | **Size/stage/primary tumor location/histology** | **Intervention** | **Primary endpoint** |
| ECOG E7296/phase II[74] | 38 patients/T2N1-2, T3-4Nany/stomach 45% GEJ 55%/adenocarcinoma 95% SCC 5% | E: neoadjuvant cisplatin, paclitaxel → surgery → 5-FU/LV + 45 Gy radiation | Tolerability: 66% grade 3/4 toxicities during neoadjuvant treatment 7.9% completed per protocol treatment |
| CALGB 80803/ Phase II[76] | 241 patients/T1N1-3M0, T2-4NanyM0 (resectable)/esophagus GEJ adenocarcinoma | E1: induction oxaliplatin, 5-FU/LV OR E2: induction carboplatin, paclitaxel  AND PET scan → non-responders change chemotherapy arm, responders continue → chemotherapy + 50,4 Gy radiation → surgery (both arms) | pCR: 18% [95%CI (7.5-33.5)] experimental 1; and 20% [95%CI (10, 33.7)] experimental 2 of PET non-responders who switched chemotherapy arm achieved pCR |
| E1201/phase II[77] | 81 patients/II-Iva/esophagus GEJ/adenocarcinoma | E1: preoperative cisplatin, irinotecan + 45 Gy radiation → surgery → cisplatin, irinotecan OR E2: preoperative cisplatin, paclitaxel + 45 Gy radiation → surgery → cisplatin, paclitaxel | pCR: 15.4%, exact, unadjusted 90% binomial CI: 6.9%-28.1% experimental 1 and 16.7%, exact, unadjusted 90% binomial CI: 8.1%-29.0% experimental 2 achieved pCR |
| RTOG-0114/phase II[78] | 73 patients/IB-IIIB/stomach/adenocarcinoma | Gastrectomy (both arms) AND E1: cisplatin, paclitaxel, 5-FU + 45 Gy radiation OR E2: cisplatin, paclitaxel + 45 Gy radiation | DFS rate: E1 closed early due to toxicity (14.6 m DFS) 52% (95%CI: 36%-68%) experimental 2 2-yr DFS |
| NCCTG N0849/phase II[79] | 42 patients/T3-4N0, TanyN+/III-IVA/esophagus/55% GEJ 40% cardia 3.6% adenocarcinoma | E: induction docetaxel, oxaliplatin, capecitabine OR C: no induction AND oxaliplatin, 5-FU + 50.4 Gy radiation → surgery (both arms) | pCR: 33% experimental and 48% control achieved pCR |
| CALGB 80101/phase III[80] | 546 patients/IB-IV (M0)/stomach 78% (4% proximal gastric, 41% distal gastric, 15% stomach NOS, 17% multicentric) GEJ 22%/adenocarcinoma | Surgery (both arms) AND E: epirubicin, cisplatin, 5-FU → 5-FU + 45 Gy radiation → chemotherapy OR C: 5-FU/LV → 5-FU + 45 Gy radiation → chemotherapy | OS rate: 44% control *vs* 44% experimental multivariate HR 0.98 (95%CI: 0.78-1.24, *P* = 0.69) 5-yr OS |
| PRODIGE5/ACCORD17 phase II/III[81] | 259 patients/I-IVA/esophagus/adenocarcinoma 14% SCC 86% | E: oxaliplatin, 5-FU/LV + 50 Gy radiation OR C: cisplatin, 5-FU + 50 Gy radiation | mPFS: 9.7 m experimental *vs* 9.4 m control HR 0.93 (95%CI: 0.70-1.24, *P* = 0.64) |

mOS: Median overall survival; mDFS: Median disease-free survival; mPFS: Median progression-free survival; E: Experimental; C: Control; HR: Hazard ratio; 5-FU: 5-fluorouracil; LV: Leucovorin; Gy: Gray; S-1: Tegafur/gimeracil/oteracil; pCR: Pathologic complete response; PET: Positron emission tomography; GEJ: Gastroesophageal junction; CRT: Chemoradiation; AEG: Adenocarcinomas of the esophagogastric junction.

**Table 5 Ongoing clinical trials**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study name/phase** | **Size/stage/primary tumor location/histology** | **Intervention** | **Primary endpoint** |
| NCT02730546/Phase Ib/II suspended | 68 patients/IB-IIIB/GEJ cardia/adenocarcinoma | E: carboplatin, paclitaxel + radiation or 5-FU, oxaliplatin, leucovorin + pembrolizumab → surgery | pCR and 1-yr PFS rate |
| PROCEED/phase II/NCT03064490 recruiting | 38 patients/locally advanced stomach GEJ esophagus/adenocarcinoma | E: carboplatin, paclitaxel + 45 Gy radiation + pembrolizumab → surgery → pembrolizumab | pCR |
| NCT03257163/phase II recruiting | 40 patients/IB-IIIC/gastric adenocarcinoma MSI or EBV positive | E: pembrolizumab → surgery → pembrolizumab + capecitabine + radiation | 3-yr RFS rate |
| NCT03776487/phase I/II recruiting | 30 patients/0-IVA/stomach GEJ/adenocarcinoma | E: oxaliplatin, 5-FU + nivolumab, ipilimumab + radiation → surgery → nivolumab | Tolerability |
| NCT00857246/phase II/completed | 30 patients/T3N0, T4, TanyN1-3, M0/stomach GEJ | E: induction cisplatin, irinotecan + cetuximab → surgery → cetuximab + 5-FU/LV + 37.5 Gy radiation | RR |
| NCT01183559/phase I/completed | 9 patients/potentially resectable/esophagus GEJ stomach | E: vandetanib + carboplatin, paclitaxel + 5-FU + 45 Gy radiation → surgery | Maximum tolerated dose: 200 mg vandetanib |
| NCT04162665/recruiting | 36 patients/T1-T2N1, T3Nany/stomach AEG3/adenocarcinoma | E: MRI guided 25 Gy radiation + oxaliplatin, capecitabine | pCR |
| NCT04308837/phase II recruiting | 29 patients/uT3-4NanyM0/stomach | E: laparoscopic hyperthermic intraperitoneal chemotherapy → carboplatin, paclitaxel + IM radiation T>6M → gastrectomy D2 → oxaliplatin, 5-FU/LV | pCR |
| CRITICS-II/phase II/NCT02931890/recruiting[83] | 207 patients/IB-IIIC/resectable/stomach GEJ/adenocarcinoma | E1: docetaxel, oxaliplatin, capecitabine OR E2: induction docetaxel, oxaliplatin, capecitabine → carboplatin, paclitaxel + 45 Gy radiation OR E3: carboplatin, paclitaxel + 45 Gy radiation AND gastrectomy (all arms) | 1-yr EFS rate |
| Neo-CRAG/phase III | 620 patients/cT3N2/N3M0, cT4aN + M0, cT4bNanyM0/gastric adenocarcinoma | E: oxaliplatin, capecitabine + 45 Gy radiation OR C: oxaliplatin, capecitabine AND gastrectomy D2 → oxaliplatin, capecitabine (both arms) | 3-yr DFS rate |
| PREACT/phase III | 682 patients/IIB (T3N1 only)-IIIC (excluding T2N3)/stomach GEJ (excluding AEG1)/adenocarcinoma | E: S-1, oxaliplatin + 45 Gy radiation OR C: S-1, oxaliplatin AND gastrectomy D2 → S-1, oxaliplatin (both arms) | 3-yr DFS rate |
| ITACA S-2/phase III/NCT01989858/ terminated | 1180 patients/T3-4N0M0, TanyN + M0/stomach/adenocarcinoma | E1: epirubicin, oxaliplatin, capecitabine (EOX) or epirubicin, cisplatin, 5-FU (ECF) → gastrectomy → EOX or ECF OR C1: gastrectomy → EOX or ECF E2: EOX or ECF → gastrectomy → EOX or ECF → capecitabine or 5-FU + 45 Gy radiation OR C2: gastrectomy → EOX or ECF → capecitabine or 5-FU + 45 Gy | 5-yr OS rate |
| Enriched-CRT 2017/phase III/NCT03680261/not yet recruiting | 556 patients/pT2-4aN1-3M0 LVI+/stomach GEJ/adenocarcinoma | Gastrectomy D1/D2 (both arms) AND E: oxaliplatin, capecitabine or S-1 + 45 Gy radiation OR C: oxaliplatin, capecitabine or S-1 | 3-yr OS rate |
| TOPGEAR/phase III[61] | 620 patients/IB (T1N1 only)-IIIC/resectable stomach GEJ/adenocarcinoma | E: induction EOX or ECF or epirubicin, cisplatin, capecitabine (ECX) or docetaxel, oxaliplatin, 5-FU/LV (FLOT) → 5-FU or capecitabine + 45 Gy radiation OR C: induction EOX or ECF or ECX or FLOT AND gastrectomy D1+ → EOX or ECF or ECX or FLOT (all arms) | 5-yr OS rate |

mOS: Median overall survival; mDFS: Median disease-free survival; mPFS: Median progression-free survival; E: Experimental; C: Control; HR: Hazard ratio; 5-FU: 5-fluorouracil; LV: Leucovorin; Gy: Gray; S-1: Tegafur/gimeracil/oteracil; pCR: Pathologic complete response; GEJ: Gastroesophageal junction; CRT: Chemoradiation; AEG: Adenocarcinomas of the esophagogastric junction; EOX: Epirubicin, oxaliplatin, capecitabine; ECF: Epirubicin, cisplatin, 5-fluorouracil; ECX: Epirubicin, cisplatin, capecitabine; FLOT: Docetaxel, oxaliplatin, 5-fluorouracil/leucovorin.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**